Community Bank & Trust Waco Texas boosted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 0.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,570 shares of the pharmaceutical company’s stock after buying an additional 120 shares during the period. Community Bank & Trust Waco Texas’ holdings in GlaxoSmithKline plc were worth $572,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Albion Financial Group UT raised its stake in shares of GlaxoSmithKline plc by 10.2% in the third quarter. Albion Financial Group UT now owns 94,294 shares of the pharmaceutical company’s stock worth $4,067,000 after buying an additional 8,730 shares during the last quarter. Dodge & Cox purchased a new stake in shares of GlaxoSmithKline plc during the fourth quarter worth approximately $1,416,000. ProVise Management Group LLC raised its stake in shares of GlaxoSmithKline plc by 5.7% in the third quarter. ProVise Management Group LLC now owns 30,288 shares of the pharmaceutical company’s stock worth $1,306,000 after buying an additional 1,620 shares during the last quarter. Rikoon Group LLC purchased a new stake in shares of GlaxoSmithKline plc during the third quarter worth approximately $1,710,000. Finally, Marshall Wace LLP raised its stake in shares of GlaxoSmithKline plc by 34.1% in the fourth quarter. Marshall Wace LLP now owns 1,051,489 shares of the pharmaceutical company’s stock worth $40,493,000 after buying an additional 267,130 shares during the last quarter. 8.41% of the stock is owned by institutional investors and hedge funds.
Shares of GlaxoSmithKline plc (NYSE:GSK) traded down 0.88% during trading on Thursday, hitting $42.57. The stock had a trading volume of 4,635,934 shares. GlaxoSmithKline plc has a 52-week low of $37.20 and a 52-week high of $45.58. The stock has a 50 day moving average of $41.91 and a 200 day moving average of $40.32. The firm has a market cap of $104.00 billion, a PE ratio of 48.60 and a beta of 0.94.
GlaxoSmithKline plc (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.62. GlaxoSmithKline plc had a net margin of 3.11% and a return on equity of 100.68%. The firm had revenue of $9.23 billion for the quarter, compared to analysts’ expectations of $9.09 billion. On average, equities analysts anticipate that GlaxoSmithKline plc will post $2.83 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, July 13th. Stockholders of record on Friday, May 12th will be issued a dividend of $0.483 per share. This is a boost from GlaxoSmithKline plc’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, May 10th. This represents a $1.93 dividend on an annualized basis and a dividend yield of 4.54%. GlaxoSmithKline plc’s dividend payout ratio is presently 389.36%.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by sleekmoney and is the property of of sleekmoney. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://sleekmoney.com/glaxosmithkline-plc-gsk-position-raised-by-community-bank-trust-waco-texas/1853612.html.
GSK has been the subject of a number of research analyst reports. Zacks Investment Research lowered GlaxoSmithKline plc from a “buy” rating to a “hold” rating in a research report on Tuesday, January 31st. Jefferies Group LLC reaffirmed a “buy” rating on shares of GlaxoSmithKline plc in a research report on Sunday, February 19th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Monday, January 30th. Deutsche Bank AG reaffirmed a “neutral” rating on shares of GlaxoSmithKline plc in a research report on Thursday, February 9th. Finally, Kepler Capital Markets initiated coverage on GlaxoSmithKline plc in a research report on Thursday, March 9th. They issued a “reduce” rating for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $45.25.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/glaxosmithkline-plc-gsk-position-raised-by-community-bank-trust-waco-texas/1853612.html
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.